Abstract |
6-Dimethylamino-9-(beta-D-arabinofuranosyl)-9H-purine ( ara-DMAP) effectively prevented the development of rash and appreciably reduced viremia in simian varicella virus-infected monkeys. Doses of 100 and 50 mg/kg/day, administered orally, were highly effective. The lowest dose of 20 mg/kg/day was much less effective in preventing moderate viremia. However, the 20 mg/kg/day did prevent the development of rash in two of three monkeys. All three doses of ara-DMAP reduced liver infection as reflected by lower aspartate aminotransferase values in the sera of the African green monkeys. Orally administered ara-DMAP was rapidly absorbed. However, significant variation among individual monkeys in the AUC values, peak plasma levels, and plasma half-lives were observed.
|
Authors | K F Soike, J L Huang, C U Lambe, D J Nelson, M N Ellis, T A Krenitsky, G W Koszalka |
Journal | Antiviral research
(Antiviral Res)
Vol. 20
Issue 1
Pg. 13-20
(Jan 1993)
ISSN: 0166-3542 [Print] Netherlands |
PMID | 8457145
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- 6-dimethylaminopurine arabinoside
- Antiviral Agents
- Aspartate Aminotransferases
- Vidarabine
|
Topics |
- Administration, Oral
- Animals
- Animals, Wild
- Antiviral Agents
(blood, pharmacokinetics, therapeutic use)
- Aspartate Aminotransferases
(blood)
- Chickenpox
(drug therapy)
- Chlorocebus aethiops
- Drug Evaluation
- Half-Life
- Relative Biological Effectiveness
- Skin
(pathology)
- Treatment Outcome
- Vidarabine
(administration & dosage, analogs & derivatives, pharmacokinetics, therapeutic use)
- Viremia
(drug therapy)
|